Study to Investigate Oral Brepocitinib in Adults with Dermatomyositis

Brief description of study

This research study is being done to investigate how safe and effective the investigational drug brepocitinib is for treating dermatomyositis. If you agree to join the study, you will be asked to complete the following research procedures: • signing this informed consent • having reviews of your medical/health history and physical exams • checks of your vital signs and use of contraception • chest X-ray • CT (chest, abdomen, pelvis), if needed • ECG (check of your heart) • muscle checks • labs to test your blood and urine, the amount of study drug absorbed by your body and other specialty and safety related labs • checks of your breathing, if the study doctor determines these checks are necessary • photos of your skin lesions, if the study doctor determines these checks are necessary • questionnaires • receiving the study drug or placebo (the placebo does not contain any active ingredients) in pill form during the treatment part of the study. Your participation will last for about 64 weeks and include a Screening period up to 8 weeks.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Dermatomyositis
Age: Between 18 Years - 75 Years
Gender: All

Updated on 09 Mar 2024. Study ID: 852665

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).